Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 58c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $241.46 +0.30%
EPS Growth %: -20.4%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
ALZN, ASPU, OCCI, More
EPS Growth %: -20.4%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $4.21, $0.58 better than the analyst estimate of $3.63. Revenue for the quarter came in at $892.88 million versus the consensus estimate of $865.88 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2022 EPS of $16.00-$17.00, versus the consensus of $17.47.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- AMC Entertainment launches tender offer for $360M in senior notes
- Microchip Technology completes acquisition of Hailo
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
